| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 以在癌干细胞中表达的分子为靶标的癌症诊断和治疗方法 | CN201380057658.X | 2013-09-03 | CN104769431A | 2015-07-08 | 各务博; 成田一卫; 后藤义博; 林隆史 |
| 本发明提供用于确定癌恶性程度的新方法、用于癌诊断的新方法、用于确定预后的新方法、用于癌治疗的新疫苗和用于遏制癌转移的新疫苗。具体地，本发明提供一种癌恶性程度评估方法，所述方法包括测量癌组织中DDX3X表达水平的步骤、以及通过使用DDX3X表达水平来评估癌组织恶性程度的步骤。 | ||||||
| 2 | 一种检测炎症性肌病特异性自身抗体MDA5的非放射标记免疫沉淀方法及应用 | CN201610332542.8 | 2016-05-19 | CN105974124A | 2016-09-28 | 张华莉; 王莉; 左晓霞; 朱红林; 罗卉; 李懿莎; 贺维佳; 刘可; 刘梅冬; 陈广文; 肖献忠 |
| 本申请公开了一种检测炎症性肌病特异性自身抗体MDA5的非放射标记免疫沉淀方法，本发明通过提供下述方法：构建含MDA5C末端(447‑1025aa)以及N端带有Myc标签的质粒pCMV‑myc‑MDA5C，瞬时转染HEK293细胞，炎症性肌病患者的待测血清与过表达MDA5C末端的HEK293细胞裂解液进行免疫沉淀，然后进行SDS‑PAGE凝胶电泳，用c‑myc抗体检测沉淀的MDA5C末端，解决了目前国内还没有商业化的检测MDA5抗体的ELISA试剂盒以及免疫印迹膜条的问题，以及自行包被MDA5抗原的ELISA试剂盒的高成本、高假阳性率和放射标记免疫沉淀法的安全性等问题。 | ||||||
| 3 | 一种抑制肿瘤转移的方法 | CN201610280023.1 | 2016-04-29 | CN105886534A | 2016-08-24 | 刘骏; 王满平 |
| 本发明涉及生物制药领域，尤其涉及一种抑制肿瘤转移的方法；采用Crispr/cas9技术定点敲除肿瘤细胞的DP103基因；通过定点敲除肿瘤细胞的DP103基因，可以有效降低肿瘤转移能力。 | ||||||
| 4 | 水稻耐热基因TOG1及其应用 | CN201210574391.9 | 2012-12-26 | CN103898078A | 2014-07-02 | 薛勇彪; 王冬; 程祝宽; 覃宝祥; 张玉娥 |
| 本发明公开了水稻耐热基因TOG1及其编码蛋白。TOG1基因是下列核苷酸序列之一：1)SEQ？ID？No：1所示的DNA序列；2)与SEQ？ID？No：1所示的DNA序列具有90％以上同源性，且编码相同功能蛋白质的DNA序列。TOG1是具有SEQ？ID？No：2所示的氨基酸序列的蛋白质，或者是将SEQ？ID？No：2所示氨基酸序列经过一个或几个氨基酸的取代、缺失或添加且具有与SEQ？ID？No：2所示的氨基酸序列相同的活性的由SEQ？ID？No：2衍生的蛋白质。本发明还公开了通过提高TOG1表达量改善植物耐热性状并有效增加产量的方法。 | ||||||
| 5 | 癌幹細胞に発現する分子をターゲットとした癌を診断、治療する方法 | JP2015529319 | 2013-09-03 | JP2015529825A | 2015-10-08 | 博 各務; 成田 一衛; 一衛 成田; 義博 後藤; 隆史 林 |
| 【課題】本発明は、新たな、がんの悪性度判定方法、がんの診断方法及び予後判定方法、がん治療剤、及びがん転移抑制剤ワクチンを提供することを課題とする。【解決手段】がんの悪性度の評価方法であって、がん組織中のDDX3X発現量を測定する段階、及び当該DDX3X発現量に基づき当該がん組織の悪性度を評価する段階を含む方法。【選択図】なし | ||||||
| 6 | Capping prone rna polymerase enzyme and its application | JP2013504294 | 2011-04-15 | JP2013531467A | 2013-08-08 | フィリップ・ジャイス |
| 本発明は、RNAトリホスファターゼの少なくとも1つの触媒ドメイン、グアニリルトランスフェラーゼの少なくとも1つの触媒ドメイン、N 7 -グアニンメチルトランスフェラーゼの少なくとも1つの触媒ドメインおよびDNA依存性RNAポリメラーゼの少なくとも1つの触媒ドメインを含むキメラ酵素を提供する。 本発明はまた、前記キメラ酵素を含む医薬組成物および前記キメラ酵素の使用も提供する。 | ||||||
| 7 | ＴＣＦ７Ｌ２変異体並びに診断および薬物スクリーニングアッセイにおけるその使用方法 | JP2016502904 | 2014-03-14 | JP2016516720A | 2016-06-09 | グラント、ストゥルーアン、エフ．エー．; チアンファ、シア |
| 【解決手段】 T2Dの治療に有効な治療薬の同定に有用な組成物および方法を開示する。【選択図】なし | ||||||
| 8 | Capping prone rna polymerase enzyme and its application | JP2013504294 | 2011-04-15 | JP5432415B2 | 2014-03-05 | フィリップ・ジャイス |
| The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N 7 -guanine methyltransferase, and at least one catalytic domain of a DNA-dependant RNA polymerase. The invention also provides pharmaceutical composition comprising said chimeric enzyme and uses of said chimeric enzyme. | ||||||
| 9 | 抗マグロＶａｓａ抗体 | JP2010530729 | 2009-09-25 | JPWO2010035465A1 | 2012-02-16 | 吉崎 悟朗; 悟朗 吉崎; 竹内 裕; 裕 竹内; 美砂子 三輪; 尚樹 壁谷 |
| 本発明の課題は、マグロ由来の始原生殖細胞を異種のレシピエント魚類の初期胚に移植するマグロ生殖細胞の分化誘導方法において、ドナー(マグロ)由来の生殖細胞とレシピエント由来の生殖細胞とを判別するための手段を提供することにある。発明者らは、クロマグロとその他の魚類(スマ、カツオ、マサバ、ゴマサバ、マルソウダ及びヒラソウダ)のVasaアミノ酸配列を比較検討してクロマグロに特異的なアミノ酸配列領域を特定し、該クロマグロに特異的なアミノ酸配列を抗原として用いることにより、クロマグロに由来する始原生殖細胞、精原細胞、卵原細胞又は卵母細胞を特異的に認識するモノクローナル抗体を作製することに成功し、本発明を完成するに至った。 | ||||||
| 10 | Capping prone RNA polymerase enzymes and their applications | US14598874 | 2015-01-16 | US09540671B2 | 2017-01-10 | Philippe Jais |
| The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N7-guanine methyltransferase, and at least one catalytic domain of a DNA-dependant RNA polymerase. The invention also provides pharmaceutical composition comprising said chimeric enzyme and uses of said chimeric enzyme. | ||||||
| 11 | POLYNUCLEOTIDES ENCODING BREX SYSTEM POLYPEPTIDES AND METHODS OF USING SAME | US15030876 | 2014-10-14 | US20160281053A1 | 2016-09-29 | Rotem SOREK; Hila SBERRO; Tamara GOLDFARB |
| Isolated polynucleotides encoding a BREX system are provided. Accordingly there is provided an isolated polynucleotide encoding a BREX system comprising a nucleic acid sequence encoding the BREX system comprising brxC/pglY, pglZ and at least one of pglX, pglXI, brxP, brxHI, brxHII, brxL, brxD, brxA, brxB, brxF, and brxE, with the proviso that said BREX system does not comprise pglW, and wherein said BREX system confers phage resistance to a bacteria recombinantly expressing same; Also provided is an isolated polynucleotide encoding a BREX system comprising a nucleic acid sequence encoding the BREX system comprising brxC/pglY, pglZ, pglX, pglW and at least one of brxD and brxHI, and wherein said BREX system confers phage resistance to a bacteria recombinantly expressing same. Also provided are compositions and methods for conferring phage resistance to bacteria or for conferring bacterial susceptibility to phages. | ||||||
| 12 | Anti-Vasa Antibodies, and Methods of Production and Use Thereof | US14856380 | 2015-09-16 | US20160075797A1 | 2016-03-17 | David T. WEAVER; Bo ZHANG |
| Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed. | ||||||
| 13 | CELLS AND METHODS FOR PRODUCING RHAMNOLIPIDS | US14642879 | 2015-03-10 | US20150247151A1 | 2015-09-03 | Steffen SCHAFFER; Mirja WESSEL; Anja THIESSENHUSEN; Nadine STEIN |
| This invention relates to cells and nucleic acids and also use thereof for producing rhamnolipids, and also methods for producing rhamnolipids. | ||||||
| 14 | METHOD TO PREVENT CANCER METASTASIS AND INHIBIT INFLAMMATION BY INHIBITION OF P68 INTERACTION WITH CALMODULIN | US14385061 | 2013-03-13 | US20150037342A1 | 2015-02-05 | Zhi-Ren Liu; Haizhen Wang |
| Compositions and methods for inhibiting cancer cell metastasis and inflammation are disclosed. The methods generally involve administering to a subject a composition containing an agent that selectively inhibits the binding of p68 RNA helicase to calmodulin (CaM) in the cells. | ||||||
| 15 | Capping-Prone RNA Polymerase Enzymes and Their Applications | US13641584 | 2011-04-15 | US20130042334A1 | 2013-02-14 | Philippe Jais |
| The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N7-guanine methyltransferase, and at least one catalytic domain of a DNA-dependant RNA polymerase. The invention also provides pharmaceutical composition comprising said chimeric enzyme and uses of said chimeric enzyme. | ||||||
| 16 | POLYNUCLEOTIDES ENCODING BREX SYSTEM POLYPEPTIDES AND METHODS OF USING SAME | EP14796294.8 | 2014-10-14 | EP3060656A1 | 2016-08-31 | SOREK, Rotem; SBERRO, Hila; GOLDFARB, Tamara |
| Isolated polynucleotides encoding a BREX system are provided. Accordingly there is provided an isolated polynucleotide encoding a BREX system comprising a nucleic acid sequence encoding the BREX system comprising brxC/pglY, pglZ and at least one of pglX, pglXI, brxP, brxHI, brxHII, brxL, brxD, brxA, brxB, brxF, and brxE, with the proviso that said BREX system does not comprise pglW, and wherein said BREX system confers phage resistance to a bacteria recombinantly expressing same; Also provided is an isolated polynucleotide encoding a BREX system comprising a nucleic acid sequence encoding the BREX system comprising brxC/pglY, pglZ, pglX, pglW and at least one of brxD and brxHI, and wherein said BREX system confers phage resistance to a bacteria recombinantly expressing same. Also provided are compositions and methods for conferring phage resistance to bacteria or for conferring bacterial susceptibility to phages. | ||||||
| 17 | METHOD TO PREVENT CANCER METASTASIS AND INHIBIT INFLAMMATION BY INHIBITION OF P68 INTERACTION WITH CALMODULIN | EP13761542 | 2013-03-13 | EP2825562A4 | 2016-01-20 | LIU ZHI-REN; WANG HAIZHEN |
| Compositions and methods for inhibiting cancer cell metastasis and inflammation are disclosed. The methods generally involve administering to a subject a composition containing an agent that selectively inhibits the binding of p68 RNA helicase to calmodulin (CaM) in the cells. | ||||||
| 18 | CANCER DIAGNOSTIC AND THERAPEUTIC METHOD TARGETING MOLECULES EXPRESSED IN CANCER STEM CELLS | EP13779641.3 | 2013-09-03 | EP2893352A2 | 2015-07-15 | KAGAMU, Hiroshi; NARITA, Ichiei; GOTO, Yoshihiro; HAYASHI, Takashi |
| The present invention provides a novel method for determining cancer malignancy, a novel cancer diagnostic method, a novel method for determining prognosis, a novel vaccine for cancer treatment, and a novel vaccine for suppressing cancer metastasis. Specifically, the invention provides a cancer malignancy evaluation method that comprises the step of measuring a DDX3X expression level in a cancer tissue, and the step of evaluating malignancy of the cancer tissue by using the DDX3X expression level. | ||||||
| 19 | ANTI-VASA ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF | US15714823 | 2017-09-25 | US20180155445A1 | 2018-06-07 | David T. Weaver; Bo Zhang |
| Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed. | ||||||
| 20 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | US15124748 | 2015-03-12 | US09884812B2 | 2018-02-06 | Andrew Easton; Phillip Gould; Andrew Marsh |
| The invention relates to a DDX3X inhibitor for use in the treatment of pneumovirus infection in a mammal, wherein the DDX3X inhibitor may be a compound of Formula (I) wherein y, Z, R1, X, L, Ra and Rb are as defined herein. The invention also relates to compounds of Formula (I). | ||||||
QQ群二维码
意见反馈
意见反馈